CN100408085C - Snow lotus preparation for treating prostate disease - Google Patents
Snow lotus preparation for treating prostate disease Download PDFInfo
- Publication number
- CN100408085C CN100408085C CNB2006100842950A CN200610084295A CN100408085C CN 100408085 C CN100408085 C CN 100408085C CN B2006100842950 A CNB2006100842950 A CN B2006100842950A CN 200610084295 A CN200610084295 A CN 200610084295A CN 100408085 C CN100408085 C CN 100408085C
- Authority
- CN
- China
- Prior art keywords
- prostate
- group
- suppository
- saussureae involueratae
- herba saussureae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 240000002853 Nelumbo nucifera Species 0.000 title claims abstract description 19
- 235000006508 Nelumbo nucifera Nutrition 0.000 title claims abstract description 19
- 235000006510 Nelumbo pentapetala Nutrition 0.000 title claims abstract description 19
- 208000017497 prostate disease Diseases 0.000 title claims abstract description 18
- 210000002307 prostate Anatomy 0.000 claims abstract description 104
- 239000003814 drug Substances 0.000 claims abstract description 95
- 201000007094 prostatitis Diseases 0.000 claims abstract description 34
- 239000004863 Frankincense Substances 0.000 claims abstract description 18
- 208000013507 chronic prostatitis Diseases 0.000 claims abstract description 14
- 125000005456 glyceride group Chemical group 0.000 claims abstract description 11
- 206010020718 hyperplasia Diseases 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 241000628997 Flos Species 0.000 claims description 20
- 239000011812 mixed powder Substances 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- 239000000341 volatile oil Substances 0.000 claims description 18
- 241000717739 Boswellia sacra Species 0.000 claims description 17
- 241001057584 Myrrha Species 0.000 claims description 17
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 15
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 15
- 238000007796 conventional method Methods 0.000 claims description 12
- 230000006837 decompression Effects 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 10
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000005325 percolation Methods 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 210000002229 urogenital system Anatomy 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 21
- 206010061218 Inflammation Diseases 0.000 abstract description 14
- 206010020880 Hypertrophy Diseases 0.000 abstract description 12
- 230000004054 inflammatory process Effects 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 208000004880 Polyuria Diseases 0.000 abstract description 5
- 230000035619 diuresis Effects 0.000 abstract description 5
- 230000036592 analgesia Effects 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 abstract description 4
- 240000007311 Commiphora myrrha Species 0.000 abstract description 3
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract description 3
- 230000003115 biocidal effect Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 244000020518 Carthamus tinctorius Species 0.000 abstract description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract description 2
- 240000009138 Curcuma zedoaria Species 0.000 abstract description 2
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 abstract description 2
- 206010030113 Oedema Diseases 0.000 abstract description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 239000003228 hemolysin Substances 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 235000019509 white turmeric Nutrition 0.000 abstract description 2
- 241000295644 Staphylococcaceae Species 0.000 abstract 2
- YNCMLFHHXWETLD-UHFFFAOYSA-N pyocyanin Chemical compound CN1C2=CC=CC=C2N=C2C1=CC=CC2=O YNCMLFHHXWETLD-UHFFFAOYSA-N 0.000 abstract 2
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 235000011030 Lithospermum officinale Nutrition 0.000 abstract 1
- 240000004035 Lithospermum officinale Species 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 abstract 1
- 241000589886 Treponema Species 0.000 abstract 1
- 241001502500 Trichomonadida Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 239000000829 suppository Substances 0.000 description 95
- 241000700159 Rattus Species 0.000 description 73
- 241000699670 Mus sp. Species 0.000 description 43
- 210000000664 rectum Anatomy 0.000 description 32
- 238000000034 method Methods 0.000 description 29
- 239000007788 liquid Substances 0.000 description 25
- 231100000331 toxic Toxicity 0.000 description 25
- 230000002588 toxic effect Effects 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 24
- 230000037396 body weight Effects 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 21
- 210000004400 mucous membrane Anatomy 0.000 description 18
- 210000000436 anus Anatomy 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 238000011047 acute toxicity test Methods 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 235000010445 lecithin Nutrition 0.000 description 16
- 239000000787 lecithin Substances 0.000 description 16
- 229940067606 lecithin Drugs 0.000 description 16
- 239000013641 positive control Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000013642 negative control Substances 0.000 description 15
- 230000003203 everyday effect Effects 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 12
- 210000004907 gland Anatomy 0.000 description 12
- 230000036407 pain Effects 0.000 description 12
- 230000008961 swelling Effects 0.000 description 12
- 230000000007 visual effect Effects 0.000 description 12
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 208000005189 Embolism Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 9
- 206010018691 Granuloma Diseases 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 231100000460 acute oral toxicity Toxicity 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 235000010418 carrageenan Nutrition 0.000 description 6
- 229920001525 carrageenan Polymers 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 230000001926 lymphatic effect Effects 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000000630 rising effect Effects 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 5
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 206010020565 Hyperaemia Diseases 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000002175 menstrual effect Effects 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 4
- 231100000403 acute toxicity Toxicity 0.000 description 4
- 230000007059 acute toxicity Effects 0.000 description 4
- 230000000680 avirulence Effects 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 231100001252 long-term toxicity Toxicity 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000004303 peritoneum Anatomy 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 240000001624 Espostoa lanata Species 0.000 description 3
- 235000009161 Espostoa lanata Nutrition 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 241000130764 Tinea Species 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 241001608538 Boswellia Species 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241001071917 Lithospermum Species 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 210000003815 abdominal wall Anatomy 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 231100000313 clinical toxicology Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000130784 Arnebia euchroma Species 0.000 description 1
- 241001050829 Arnebia guttata Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010069918 Bacterial prostatitis Diseases 0.000 description 1
- 235000018062 Boswellia Nutrition 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 241000963421 Curcuma kwangsiensis Species 0.000 description 1
- 235000003397 Curcuma kwangsiensis Nutrition 0.000 description 1
- 240000005629 Curcuma phaeocaulis Species 0.000 description 1
- 235000003391 Curcuma phaeocaulis Nutrition 0.000 description 1
- 241000963390 Curcuma wenyujin Species 0.000 description 1
- 235000003394 Curcuma wenyujin Nutrition 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010066364 Hypersexuality Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 241000029132 Paronychia Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 241001180441 Sparganium stoloniferum Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 229940061641 androsterone Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 206010003883 azoospermia Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000019884 chronic gingivitis Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000027692 gas pain Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 208000008634 oligospermia Diseases 0.000 description 1
- 230000036616 oligospermia Effects 0.000 description 1
- 231100000528 oligospermia Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 231100000916 relative toxicity Toxicity 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000008554 xiao zhi ling Substances 0.000 description 1
Abstract
The present invention relates to a snow lotus preparation for treating prostate diseases, which is made of raw material medicine of snow lotuses, gromwells, zedoaries, safflowers, breed tubers, frankincense and myrrh and auxiliary material of glyceride of mixed fatty acid and lauryl sodium sulfate, and is medicine for external use for treating prostate and prostate hyperplasia (hypertrophy). Proved by a tryout result, the present invention has the advantages of antibiosis, inflammation relief and analgesia, enhances the immunity of machine bodies, notably suppresses the prostate hyperplasia, enhances the generation of blood serum and hemolysin, enhances the content of blood serum bacteriolysis, clears various surplus free radicals in the bodies, and enhances the activity of antioxidant enzyme. Simultaneously, envelope wall breaking factors with high concentration are contained to make the snow lotus preparation for treating prostate diseases have a direct bactericidal function to golden brown staphylococci, colibacillus, protei, epidermal staphylococci, pyocyanine, white candida, treponemas, gonorrhoeae diplococcus, trichomonads, etc. The snow lotus preparation for treating prostate diseases has the advantages of clearing away heat, detoxicating, activating blood circulation, dissipating blood stasis, inducing diuresis and reducing edema, has effective speed to incurable chronic prostatitis and the prostate hyperplasia (the hypertrophy). Simultaneously, treatment of principal and subordinate symptoms is carried out, with original efficacy.
Description
Technical field
The present invention relates to snow lotus preparation for treating prostate disease of the acute and chronic prostatitis of a kind of control, prostatic hyperplasia genitourinary system such as (hypertrophys) and preparation method thereof.
Background technology
Prostatitis and prostatic hyperplasia are male's commonly encountered diseases, and this disease is strict to influence patient's physical and mental health and quality of life, has caused the world of medicine's extensive concern.Chronic prostatitis can be divided into bacillary and non-bacterial two big classes, its cause of disease, pathology complexity, and the special anatomical features of prostate in addition, (having blood-prostate barrier), its conventional antibiotic therapy method is DeGrain often.Present radio-frequency (RF) thermotherapeutic, Therapeutic Method such as melt in the per urethra prostata tissue and obtained certain therapeutic advance, but range of application is limited, though operative treatment has advance, but operating technology there is higher requirement, complication such as urinary incontinence, hangover of gland and TURP syndrome may occur if operation is not held concurrently.
Drug treatment, owing to doctor trained in Western medicine also makes further progress to the prostatic hyperplasia Study of Etiology, so the effect of treatment with western is satisfied not enough.Treatment at present mainly concentrates on the e receptor blocking; 5 alpha-reductases suppresses; hormone therapy several aspects such as (anti-androsterone treatment are main); obtained certain curative effect; but the patient often suffers from dizziness, orthostatic hypotension simultaneously; sexual disorder appears in part patient, phenomenons such as endocrine dysfunction, and drug price costliness.
Summary of the invention
The object of the invention is that series preparation is the training medication of treatment prostatitis and prostatic hyperplasia (hypertrophy) before the Herba Saussureae Involueratae of development.Said preparation is by crude drug Herba Saussureae Involueratae, Radix Arnebiae (Radix Lithospermi), Rhizoma Curcumae, Flos Carthami, rhizoma sparganic, Olibanum and Myrrha, and adjuvant is that mixed fatty glycerides and 1% sodium lauryl sulphate are made; Result of the test shows, before Lenin's oral liquid share snow lotus preparation for treating prostate disease and have antibiotic, antiinflammatory, analgesia, enhancing human body immunity power, significantly suppress prostatic hyperplasia, improve the serum hemolysin generation and improve serum bacteriolyze content, remove various unnecessary free radicals in the body, improve the activity of antioxidase, include the high concentration peplos breaking cellular wall factor simultaneously, make this medicine focus of going directly, staphylococcus aureus, escherichia coli, Bacillus proteus, staphylococcus epidermidis, bacillus pyocyaneus, Candida albicans, treponema pallidum, gonorrhea diplococcus, infusorian etc. are had direct bactericidal action.Clinical research shows, this product heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, inducing diuresis to remove edema have onset rapid to cureless chronic prostatitis and prostatic hyperplasia (hypertrophy), the treating both the principal and the secondary aspects of a disease at the same time unique effects.Through a large amount of retrieval, do not see frequent micturition due to the treatment prostatitis that above a few flavor medical material compatibility makes, urgent micturition, dysurea, waist is aching and limp, the dripping turbid preparation that waits disease, and wherein chemistry, pharmacology and clinical practice document of each flavor are more.
Snow lotus preparation for treating prostate disease of the present invention; said preparation is by crude drug Herba Saussureae Involueratae, Radix Arnebiae (Radix Lithospermi), Rhizoma Curcumae, Flos Carthami, rhizoma sparganic, Olibanum and Myrrha; adjuvant is that mixed fatty glycerides and 1% sodium lauryl sulphate are made, and the content of per 1000 or piece each component is: Herba Saussureae Involueratae 500-600g, Flos Carthami 350-400g, Radix Arnebiae (Radix Lithospermi) 1100-1150g, Rhizoma Curcumae 620-690g, rhizoma sparganic 620-690g, Olibanum 150-200g, Myrrha 150-200g, mixed fatty glycerides 1.40-1.80kg and sodium lauryl sulphate 15-20g.
The preparation method of snow lotus preparation for treating prostate disease follows these steps to carry out:
A, will Olibanum, Myrrha is ground into fine powder after concocting, and crosses 100 mesh sieves, mixing is standby;
B, Rhizoma Curcumae are ground into coarse powder, add 8 times of water gagings, extract volatile oil according to a conventional method 6 hours, and volatile oil device is in addition collected, and is standby;
C, medicinal residues and Herba Saussureae Involueratae, Flos Carthami, rhizoma sparganic add 10 times of amount 80% alcohol reflux 3 times, each 1.5 hours, merging filtrate filters, and it is 1.15～1.20 clear paste that filtrate decompression is concentrated into relative density, vacuum drying gets dry extract, pulverize, mixes mistake 100 mesh sieves with fine powder after above-mentioned Olibanum, Myrrha are pulverized, as mixed powder, standby;
D, Radix Arnebiae (Radix Lithospermi) add 12 times of amount 95% ethanol and carry out percolation with the speed of per minute 7ml, collect percolate, and be to thick paste, standby at decompression recycling ethanol below 60 ℃;
E, take by weighing S by the amount of 2.3 times of mixed powders
36Mixed fatty glycerides and 1% sodium lauryl sulphate; be heated to molten condition; add mixed powder and thick paste; fully stir evenly, the volatile oil that adds during to 45 ℃ to be cooled continues to be stirred to evenly; inject the bolt mould; take out cooling back, make 1000 or piece, or make paste according to a conventional method and get final product.
Snow lotus preparation for treating prostate disease prevents, treats the purposes of the external used medicine of acute and chronic prostatitis, prostatic hyperplasia, prostate hyperplasia as preparation.
Using method of the present invention: preceding the rising with morning of sleeping filled in medicine anus 4-6 centimeters after an action of the bowels, and every day 2 times, each one piece or one, one month is a course of treatment.
Snow lotus preparation for treating prostate disease of the present invention is to choose pure natural Uigurs medicines such as Herba Saussureae Involueratae according to the theory that the Uygur medicine pharmacy shows unique characteristics, cause vitality, mentality, the insufficient sign of natural agent at " vara rice I the Mai Zi of Germany and Italy ", prescription emphasizes to strengthen human life power, mentality, natural agent, effects such as maturation and the interior unusual body fluid of removing body, develop last my bolt of Herba Saussureae Involueratae, Herba Saussureae Involueratae last I loose, Herba Saussureae Involueratae prostatitis pad, and share with preceding Lenin's oral liquid, for treatment prostatitis and prostatic hyperplasia (hypertrophy) provide new tool and new method.
Snow lotus preparation for treating prostate disease of the present invention is a foundation with uighur medicine scientific principle opinion, adopt the refining pure natural Uygur medicine type external suppository that forms of modern pharmaceutical technology, include the high concentration peplos breaking cellular wall factor, make this medicine focus of going directly, to cureless chronic prostatitis and prostatic hyperplasia (hypertrophy) have onset rapidly, the unique effects for the treatment of both the principal and the secondary aspects of a disease at the same time.This medicine is not found toxic and side effects, and nonirritant does not have irritated reaction, steady quality, and the medicine source is abundant, and is easy to use etc.
The pharmacological properties of snow lotus preparation for treating prostate disease of the present invention is:
Herba Saussureae Involueratae: this product is the dry low top of feverfew Herba Saussureae Involueratae Saussure ' a involucrateKar.et.Kin..The property of medicine is xeothermic, bitter in the mouth, suffering, and is poisonous.Have to give birth to do and give birth to heat, dispeiling pathogenic wind and removing dampness, bone and muscle strengthening, anti-inflammatory analgetic, vulcanize kidney, hypersexuality, promoting blood circulation to restore menstrual flow, tire is urged in the temperature palace, and effects such as cold relieving leukorrhagia stopping are used for raw property or lymphatic temperament disease, catch cold rheumatic arthritis, arthralgia as the waist kidney, kidney is cold empty, hyposexuality, through water not down, under the Placenta Hominis difficulty, lower abdomen cold, diseases such as leucorrhoea grow in quantity.
Flos Carthami: be the dried floral of feverfew Flos Carthami Carthamus tinctorius L..Property of medicine secondary is xeothermic.Have to give birth to do and give birth to heat, promoting blood circulation to restore menstrual flow, ripe unusual lymphatic temperament, nourishing and fit keeping function, enriching blood blazes, and dampness is removed tinea, the antiinflammatory detumescent, the diuresis replenishing essence, relieving cough and asthma, the warm blood tonifying YANG, convergence removes effects such as rash.Be used for raw property or lymphatic temperament disease, as menoxenia, dysuria, oligospermia sexual impotence, cough with copious phlegm, asthma out of breath, vitiligo, white macula disease, eczema, oral ulcer etc.
Radix Arnebiae (Radix Lithospermi): be the dry root of comfrey lithospermum euchromum Royle Arnebia euchroma (Royle) Johnst., Radix Arnebiae (Radix Lithospermi) Lithospermum erythrorhizonSieb.etZucc. or arnebia guttata Bunge Arnebiaguttata Bunge.The property of medicine is done cold.Have to give birth to do to give birth to and tremble with fear promoting blood circulation to restore menstrual flow, effects such as eliminating inflammation and expelling toxin.Be used for humid disease such as hepatitis, measles without adequate eruption, carbuncle, diseases such as scabies.
Rhizoma Curcumae: be the dry rhizome of zingiberaceous plant Rhizoma Curcumae Curcuma phaeocaulis Val., Guangxi zedoary Curcuma kwangsiensis S.G.Lee et C.F.Liang or RADIX CURCUMAE Curcumawenyujin Y.H.Chen et C.Ling.Property of medicine secondary is xeothermic, acrid in the mouth.Have to give birth to do and give birth to heat, open retardance, the warming the meridian detumescence, the gas pain relieving of loosing, promoting blood circulation to remove obstruction in the collateral, warm waist tonifying YANG, the supplementing the brain heart tonifying, invigorating the stomach and promoting digestion, warming the kidney to invigorate YANG, diuresis is stimulated the menstrual flow, sending down the abnormal ascending QI emesis, effects such as strong flesh teeth consolidating.Be used for raw property or lymphatic temperament disease, as the swollen and pain of various inflammation that retardance causes, cough, asthma, lower abdominal distention pain, arthralgia, the stomachache poor appetite, the lumbago sexual impotence, infrequent menstruation is not smooth, nausea and vomiting, odontoseisis, chronic gingivitis.
SANLING: for the dry stem of rhizoma scirpi plant rhizoma scirpi Sparganium stoloniferum Buch.-Ham. fast.The property of medicine is xeothermic.Has blood-activating and qi-promoting, effects such as removing obstruction for relieving pain.Be used for the blood stasis amenorrhea, diseases such as food stagnation distending pain.
Olibanum: for Burseraceae Boswellia carterii Boswellia carterii Birdw. and congener B.bhaw-dijiana Birdw. bark ooze out resin.The dried secondary heat of property of medicine one-level, acrid in the mouth, hardship.Have to give birth to do and give birth to heat, the antiinflammatory detumescent is removed the tinea wound healing, convergence granulation promoting, antiasthmatic-antitussive, stomach warming emesis, invigorating the stomach and promoting digestion, effects such as controlling nocturnal emission with astringent drugs reducing urination.Be used for raw property or lymphatic temperament brain diseases, as moist brain void, paronychia, mastitis, encelitis is swollen, and seminal fluid is not solid, the frequent micturition incontinence, tinea capitis, burn, nebula, diseases such as various skin infection are given birth in the canthus.
Myrrha: be olive subject plant Herba Violae tree Commiphora myrrha Engl., breathe out the dry resin of Herba Violae tree Commiphora molmol Engl..Property of medicine secondary is xeothermic, bitter in the mouth, suffering.Have the heat of give birth to do giving birth to, the damp eliminating pain relieving of tremble with fear, softening the hard mass removes tumor, and remove tinea and more create, the cold relieving cough-relieving, drying dampness to eliminate phlegm, erosion prevention and muscle growing stimulates the menstrual flow, effects such as diuresis detoxifcation.Be used for raw property or lymphatic temperament disease, as raw property arthralgia, sciatica, oral cavity pain, have sore throat cold cough, moist abundant expectoration, bronchiectasis, eczema abscess, menoxenia, dysuria etc.
The present invention amplifies production according to this production technology, obtains the suppository of three batches of amplifications, its outward appearance, melts the key property that becomes suppositorys such as time limit and all meets " the pertinent regulations under 2000 editions suppository items of Chinese pharmacopoeia.
Snow lotus preparation for treating prostate disease of the present invention was observed 6 months under long-term reserved sample observing 12 months, acceleration environment, significant change does not all take place in sample appearance, character, discriminating, hardness, content uniformity, disintegration, microbial limit and content, shows that this quality of the pharmaceutical preparations is stable, package materials selection is appropriate.
The pharmacological toxicology research of snow lotus preparation for treating prostate disease of the present invention:
Main pharmacodynamics research:
Experimental animal: Kunming mouse, Wistar rat, available from the big medical experiment animal center of Xinjiang medical courses in general, the certificate of competency: No. 16003, the moving word of Xinjiang doctor.
(1) the Herba Saussureae Involueratae prostate suppository causes bullate influence to mice foot sole of the foot carrageenin
Method and result: get 80 of Kunming kind white mice, body weight 20 ± 2g, be male, divide 8 groups at random, administration fasting in preceding 4 hours, every day 1 time, rectally is 7 days continuously, and filled in anus 4 hours with spongy embolus, injected the subcutaneous inflammation that causes of the right back sufficient sole of the foot of mice with 1% carrageenin 0.05ml in 1 hour after the last administration, cause scorching back 1,2,3,4,5, measured sufficient sole of the foot thickness with outside micrometer in 6 hours, so that the difference of the sufficient sole of the foot is organized a mean t check for the swelling degree before and after scorching, and the results are shown in Table 1 according to " (blank group swelling degree-administration group swelling degree)/blank group swelling degree ":
Table 1 Herba Saussureae Involueratae prostate suppository causes bullate influence (X ± SD n=10) to mice foot sole of the foot carrageenin
Administration group and blank group group compare,
* *P＜0.01,
*P＜0.05,
*P＞0.05.
As seen from Table 1, Herba Saussureae Involueratae prostate suppository various dose and positive control drug Flos Chrysanthemi Indici suppository rectally, on Carrageenan induced mice pedal swelling all has significant inhibitory effect.Show that Herba Saussureae Involueratae prostate suppository on Carrageenan induced mice acute exudative inflammation has significant antiinflammatory inhibitory action.
(2) the Herba Saussureae Involueratae prostate suppository is to the bullate influence of mice auricular concha caused by dimethylbenzene xylene
Method and result: get 50 of mices, body weight 20 ± 2g is male.Divide 5 groups and rectally at random, administration fasting in preceding 4 hours, every day 1 time, successive administration 7 days, and filled in anus 4 hours with spongy embolus, after the last administration 30 minutes, every group of mouse right ear two sides smeared dimethylbenzene 0.1ml and caused inflammation, caused scorching 2 hours and take off neck to put to death animal, get same position, left and right sides auricle with the 8mm card punch, weighing, is the swelling degree with two auricle weight differences, organizes a mean t check.And, the results are shown in Table 2 according to " (the average swelling degree of the blank group-average swelling degree of administration group)/average swelling degree of blank group group " calculating inflammation suppression ratio.
Table 2 Herba Saussureae Involueratae prostate suppository is to the bullate influence of mice auricular concha caused by dimethylbenzene xylene (X ± SD)
Administration group and blank group compare,
* *P＜0.01.
As seen from Table 2, the Herba Saussureae Involueratae prostate suppository is little, in, behind big three kinds of dosage and the positive control medicine suppository of wild chrysanthemum flower agent rectally, the two shell inflammation swelling of xylol induced mice all have significant inhibitory effect.Show that the Herba Saussureae Involueratae prostate suppository has stronger inhibitory action to acute exudative inflammation.
(3) the Herba Saussureae Involueratae prostate suppository is to the swollen influence that forms of rat granuloma
Method and result: get 40 of wistar rats, body weight 200 ± 20g.The Herba Saussureae Involueratae prostate suppository group that is divided into blank group, Flos Chrysanthemi Indici suppository positive controls and 3 various dose according to the body weight equilibrium at random.Each rat is under the ether light anaesthesia, and left and right sides groin is respectively cut an osculum, expands subcutaneous tissue with vascular forceps, and every side is imbedded 20mg sterilization cotton balls, then sews up.Postoperative began rectally the same day, every day 1 time, and filled in anus 4 hours, continuous 7 days with spongy embolus.Pulling cervical vertebra on the 8th day puts to death, cut open and get cotton balls, pick most fat, it is heavy to deduct cotton balls after weighing, be the clean weight in wet base of granuloma, with t check between the clean wet weight mean of each group granuloma work group, and, the results are shown in Table 3 according to " (the clean weight in wet base of the blank group granuloma-clean weight in wet base of administration group granuloma)/clean weight in wet base of blank group granuloma " calculating suppression ratio.
Table 3 Herba Saussureae Involueratae prostate suppository is to the swollen influence that forms of rat granuloma (X ± SD)
Administration blank group compares with group:
* *P＜0.01.
As seen from Table 3, little with the Herba Saussureae Involueratae prostate suppository, in, big three kinds of dosage or the continuous rectally of positive control drug Flos Chrysanthemi Indici suppository 7 days, bullate formation all has significant inhibitory effect to rat granuloma.Show that the Herba Saussureae Involueratae prostate suppository also has the obvious suppression effect to proliferative inflammation.
(4) the Herba Saussureae Involueratae prostate suppository is to the influence of rat dry yeast artificial fever
Method and result: get 40 of Wistar male rats, 200 ± 20g, what be divided into blank group and 3 dosage at random is tried thing group and positive controls, administration fasting in preceding 4 hours, simultaneously dips in normal saline insertion anus with bare headed Glass rod earlier before the administration, rectally behind the abundant defecation of stimulation in rats, and filled in anus 4 hours with spongy embolus, every day 1 time, continuous 7 days.Survey basal body temperature before the last administration earlier, each Mus of 1h subcutaneous injection 20g/dl yeast suspension 1ml/100g in the back immediately after the administration, after this 0.5,1,2,4,6,8,10,12h respectively surveys animal heat once, surveyed anus temperature and basic anus using warming therapy difference with different time, index for the body temperature variation, each group is carried out statistical procedures, the results are shown in Table 4.
Table 4 Herba Saussureae Involueratae prostate suppository is to the influence (X ± SD, n=8) of rat dry yeast artificial fever
Administration group and blank group compare,
* *P＜0.01,
*P＜0.05,
*P＞0.05.
As seen from Table 4, behind the subcutaneous injection yeast of the rat back suspension, body temperature has rising by a relatively large margin, behind Herba Saussureae Involueratae prostate suppository and the positive control drug rectally, more all can make rat fever body temperature that remarkable reduction effect is arranged with the blank group, show that the Herba Saussureae Involueratae prostate suppository has refrigeration function when heavy dose of.
(5) the Herba Saussureae Involueratae prostate suppository is to the analgesic activity of mice
1, mice hot plate method
Method and result: choose the Healthy female mice, earlier each Mus is placed respectively on 55 ± 0.5 ℃ of hot plates, with mice kicking, to lick metapedes, jump be the pain reaction index, selects 50 of the qualified mices that pain reaction was no more than for 30 seconds incubation period, body weight 20 ± 2g, what be divided into blank group and 3 dosage at random is tried thing group and positive controls, rectally, administration fasting in preceding 4 hours, every day 1 time, and filled in anus 4 hours, successive administration 7 days with spongy embolus.After the last administration, begin to measure 15 minutes, 30 minutes, 60 minutes pain thresholding, and calculate threshold of pain raising percentage rate according to " average pain threshold * 100% before (the preceding average pain threshold of average pain threshold one medication after the medication)/medication ".The results are shown in Table 5.
Table 5 Herba Saussureae Involueratae prostate suppository is to the analgesic activity (mice hot plate method) of mice (X ± SD)
Administration group and blank group compare,
* *P＜0.01,
*P＜0.05.
As seen from Table 5, the Herba Saussureae Involueratae prostate suppository is little, in, behind big three kinds of dosage and the positive control drug rectally, all have significant analgesic activity.
2, mouse writhing method
Method and result: get 50 of healthy male mices, body weight 20 ± 2g is tried thing group and positive controls according to what the body weight equilibrium divided physiology saline control group and 3 dosage at random, rectally, and every day 1 time, and filled in anus 4 hours, successive administration 7 days with spongy embolus.After the last administration 1 hour, the equal ip0.6% acetic acid of each Mus 0.2ml, and write down and turn round writhing response in body incubation period and the 15min (abdominal part indent, stretch hind leg, buttocks is raised) number of times behind each Mus ip acetic acid, with the index of writhing response number of times as the analgesic activity comparison, organize a mean t check, and calculate the analgesia percentage rate according to " (the blank group is on average turned round body number of times-medication group and on average turned round the body number of times)/blank group is on average turned round the body number of times ".The results are shown in Table 6.
Table 6 Herba Saussureae Involueratae prostate suppository is to the analgesic activity (mouse writhing method) of mice (X ± SD)
Administration group and blank group compare,
* *P＜0.01.
As seen from Table 6, the Herba Saussureae Involueratae prostate suppository is little, in, behind big three kinds of dosage and the positive control drug rectally, (stomachache reaction) has significant inhibitory effect to the caused writhing response of mouse peritoneal injection acetum, shows that the Herba Saussureae Involueratae prostate suppository has significant analgesic activity.
(6) influence of Herba Saussureae Involueratae prostate suppository Dichlorodiphenyl Acetate induced mice peritoneum inflammatory exudation
Method and result: get 50 of male mices, body weight 20 ± 2g, grouping and medication are the same, continuous 7 days.1h after the last administration, the equal iv of each Mus give 0.5% azovan blue normal saline solution 5ml/kg, and ip0.6% acetic acid 10ml/kg immediately.20min puts to death mice behind ip acetic acid, use the normal saline flushing abdominal cavity, collect whole flushing liquors to 10ml, get supernatant after centrifugal and measure its OD value,, reflect the degree of peritoneum inflammatory exudation indirectly with the concentration of azovan blue in the OD value representation flushing liquor in ultraviolet spectrophotometer 578nm wavelength place, compare with the blank group, t check between the work group, and, the results are shown in Table 7 according to " (the average OD value of the blank group-average OD value of administration group)/average OD value of blank group " calculating suppression ratio:
The influence of table 7 Herba Saussureae Involueratae prostate suppository Dichlorodiphenyl Acetate induced mice peritoneum inflammatory exudation (X ± SD)
Administration group and blank group compare,
* *P＜0.01,
*P＜0.05,
*P＞0.05.
As seen from Table 7, the Herba Saussureae Involueratae prostate suppository is little, in, behind big three kinds of dosage and the positive control drug rectally, the Herba Saussureae Involueratae prostate suppository has the obvious suppression effect to the mouse peritoneum inflammatory exudation when heavy dose of, positive control drug Flos Chrysanthemi Indici suppository also has significant inhibitory effect.
(7) the Herba Saussureae Involueratae prostate suppository is to the therapeutical effect of chronic prostatitis
1. the Herba Saussureae Involueratae prostate suppository is to the prostatitic therapeutical effect of rat chronic due to the escherichia coli
Experimental technique: choose 60 of Wistar male rats, body weight 240-280g is divided into dosage group (V) in normal group (I), model group (II), Flos Chrysanthemi Indici suppository group (III), Herba Saussureae Involueratae prostate suppository small dose group (IV), the Herba Saussureae Involueratae prostate suppository, the heavy dose of group of Herba Saussureae Involueratae prostate suppository (VI) according to the body weight equilibrium.
Except that the normal control group, all the other 5 groups of rat administration 1 Zhou Houjun are with etherization, after waiting to anaesthetize, wipe out lower abdomen by hair, the abdomen median line is cut down stomach wall open in the aseptic condition lower edge, mentions prostate gently with tweezers, injects the good escherichia coli (1 * 10 of dilution in advance respectively in both sides
7) each 0.2ml, send attached internal organs, sew up abdominal wall muscle skin, put back to mouse cage.After the modeling, it is relatively poor that each organizes the rat mental status, and movable the minimizing is off one's feed, but all progressively recover in postoperative beginning in the 3rd day.Observed seven days continuously, each organizes none death of rat, and wound healing is good, and the mental status can be good, and hair color is moist, and appetite, two is just no abnormal.
Medication: each is organized rat and injects escherichia coli in administration after seven days, continues administration 3 days.Medication: administration fasting in preceding 4 hours, dip in normal saline with bare headed Glass rod earlier before the administration simultaneously and insert anus, the abundant defecation of stimulation in rats.Then, suppository is pressed dosed administration shown in the table 8, and filled in anus 4 hours, every day 1 time, successive administration 10 days with spongy embolus.
The observation of prostate lecithin: the full visual field of lecithin: ++ ++; The lecithin 3/4 full visual field: +++; The lecithin 1/2 full visual field: ++; The lecithin 1/4 full visual field :+.
Experimental result:
Influence to experimental rat prostate anatomic form
Normal group prostate surface is ruddy glossy, and gland tissue is soft and flexible, does not have adhesion with surrounding tissue, is easy to separate; The extensive adhesion of model group body of gland and surrounding tissue, the canescence lamellar tuberosity that as seen more or less, elasticity is relatively poor, and volume is more normally organized little.The suppository of wild chrysanthemum flower matched group, body of gland is glossy, color and luster is light slightly, softness still can, no tuberosity.4 rat bodies of gland and the slight adhesion of surrounding tissue are wherein arranged; The slight adhesion of small dose group and surrounding tissue, visible a small amount of canescence lamellar tuberosity, elasticity is poor slightly, and volume is more normally organized slightly little; Middle dosage group, the gland tissue softness, with the slight adhesion of surrounding tissue, size changes not obvious; Heavy dose of group, the gland tissue softness is glossy, and elasticity is better, does not have adhesion with surrounding tissue, and size changes not obvious, no tuberosity.
To lecithin, leukocytic influence in the experimental rat massage of prostate liquid
Lecithin almost is covered with the visual field in the normal prostatic, and the garden is spherical, drips similarly, shinny to fat, and refractivity is strong, is evenly distributed, and it differs in size.During prostatitis, lecithin reduces, and trend in heaps is arranged.This is that during hyperphlogosis, leukocyte almost is covered with the visual field, is the blister shape because during inflammation due to a large amount of lipids of macrophage phagocytic, no leukocyte in the normal prostatic during prostate light inflammation, has small quantities of leukocytes.The results are shown in Table 8,9.
Table 8 Herba Saussureae Involueratae prostate suppository is to (the X ± SD) of the prostatitic influence of rat chronic due to the escherichia coli
Model group and normal group compare,
△ △ △P＜0.01; Administration group and model group compare,
* *P＜0.01.
Table 9 Herba Saussureae Involueratae prostate suppository is to the influence of bacterial prostatitis due to the escherichia coli (X ± SD)
Model group and normal group compare,
△ △ △P＜0.01; Administration group and model group compare,
* *P＜0.01,
*P＜0.05,
*P＞0.05.
From table 8,9 as seen, the Herba Saussureae Involueratae prostate suppository is little, in, behind big three kinds of dosage and the positive control drug rectally, rat chronic prostatitis due to the escherichia coli is had the obvious treatment effect, positive control drug Flos Chrysanthemi Indici suppository also has significant therapeutical effect.
2. the Herba Saussureae Involueratae prostate suppository is to the experimentation of nonbacterial prostatitis influence
Experimental technique: choose 60 of Wistar rats, body weight 240-280g is divided into dosage group (V) in normal group (I), model group (II), Flos Chrysanthemi Indici suppository group (III), Herba Saussureae Involueratae prostate suppository small dose group (IV), the Herba Saussureae Involueratae prostate suppository, the heavy dose of group of Herba Saussureae Involueratae prostate suppository (VI) according to the body weight equilibrium.
Except that the normal control group, all the other 5 groups of rats after waiting to anaesthetize, are wiped out lower abdomen by hair all with etherization, the abdomen median line is cut down stomach wall open in the aseptic condition lower edge, mention bladder and both sides seminal vesicle gently with tweezers, expose the prostate notopodium invest the seminal vesicle inboard (the prostate perimeter region that is equivalent to the people, and people's prostatitis mainly betides perimeter region), inject each 0.1ml of XIAOZHILING ZHUSHEYE respectively in both sides, send attached internal organs, sew up abdominal wall muscle skin, put back to mouse cage.After the modeling, it is relatively poor that each organizes the rat mental status, and movable the minimizing is off one's feed, but all progressively recover in postoperative beginning in the 3rd day.Observed seven days continuously, each organizes none death of rat, and wound healing is good, and the mental status can be good, and hair color is moist, and appetite, two is just no abnormal.
Medication: each organizes rat in postoperative beginning in the 7th day administration.Medication: dip in normal saline with bare headed Glass rod earlier before the administration fasting in preceding 4 hours, administration and insert anus, the abundant defecation of stimulation in rats.Then, suppository is according to dosage filled in rectum, and block, every day 1 time, successive administration one month with the sterilization spongy embolus.
Prostate lecithin and leukocytic observation:
The full visual field of lecithin: ++ ++; The lecithin 3/4 full visual field: +++; The lecithin 1/2 full visual field: ++; The lecithin 1/4 full visual field :+;
Experimental result:
Influence to experimental rat prostate anatomic form
Normal group prostate surface is ruddy glossy, and gland tissue is soft and flexible, does not have adhesion with surrounding tissue, is easy to separate; The extensive adhesion of model group body of gland and surrounding tissue, the canescence lamellar tuberosity that as seen more or less, elasticity is relatively poor, and volume is more normally organized little.The suppository of wild chrysanthemum flower matched group, body of gland is glossy, color and luster is light slightly, softness still can, no tuberosity.The slight adhesion of small dose group and surrounding tissue, visible a small amount of canescence lamellar tuberosity, elasticity is poor slightly, and volume is more normally organized slightly little; Middle dosage group, the gland tissue softness, with the slight adhesion of surrounding tissue, size changes not obvious; Heavy dose of group, the gland tissue softness is glossy, and elasticity is better, does not have adhesion with surrounding tissue, and size changes not obvious, no tuberosity.
To lecithin and leukocytic influence in the experimental rat massage of prostate liquid
Lecithin almost is covered with the visual field in the normal prostatic, and the garden is spherical, drips similarly, shinny to fat, and refractivity is strong, is evenly distributed, and it differs in size.During prostatitis, lecithin reduces, and trend in heaps is arranged.This is that during hyperphlogosis, leukocyte almost is covered with the visual field, is the blister shape because during inflammation due to a large amount of lipids of macrophage phagocytic, no leukocyte in the normal prostatic during prostate light inflammation, has small quantities of leukocytes.The results are shown in Table 10,11.
Table 10 Herba Saussureae Involueratae prostate suppository is to the influence of nonbacterial prostatitis (X ± SD)
Model group and normal group compare,
△ △ △P＜0.01; Administration group and model group compare,
* *P＜0.01.
Table 11 Herba Saussureae Involueratae prostate suppository is to the influence of nonbacterial prostatitis (X ± SD)
Model group and normal group compare,
△ △ △P＜0.01; Administration group and model group compare,
* *P＜0.01,
*P＜0.05,
*P＞0.05.
From table 10,11 as seen, the Herba Saussureae Involueratae prostate suppository is little, in, behind big three kinds of dosage and the positive control drug rectally, the Herba Saussureae Involueratae prostate suppository is to the effect of nonbacterial prostatitis obvious suppression in heavy dose, and positive control drug Flos Chrysanthemi Indici suppository also has significant inhibitory effect.
The result shows, Herba Saussureae Involueratae prostate suppository mice (0.5,1,2g/kg), and rat (0.4,0.8,1.6g/kg) rectally suppresses dimethylbenzene induced mice auricular concha swelling (with model group P＜0.01 relatively); Antagonism acetic acid induced mice abdominal cavity capillary permeability increases (comparing P＜0.01 with model group); Suppress carrageenin induced mice pedal swelling (comparing P＜0.01) with model group; Rat fever reaction due to the dry yeast there is antagonism (with model group P＜0.01 relatively); Writhing method and hot plate method cause on the model of pain simultaneously, reduce the writhing response number of times of mice and improve the threshold of pain (comparing P＜0.01 with model group); To showing the infiltration that suppresses inflammatory cell on the scorching animal model of bacillary rat prostate, improve prostate secretory function and anti-fibroplasia effect (comparing P＜0.01) with model group; The infiltration that suppresses inflammatory cell be can show on the scorching animal model of non-bacterial rat prostate, prostate secretory function and anti-fibroplasia effect (comparing P＜0.01) improved with model group.Above-mentioned test explanation Herba Saussureae Involueratae prostate suppository has tangible antiinflammatory, analgesia, analgesic, detumescence, fibrosis hypertrophy, improve effect such as glandular secretion function.
Acute toxicity test;
Herba Saussureae Involueratae prostate suppository clinical administration approach is a rectally, we think that rectally can not guarantee that medicine is in intrarectal long-time stop in the acute toxicity test in mice process, medicine can not fully absorb, the toxic reaction that shows can not demonstrate fully the toxic reaction of medicine, therefore we select its mouse oral route of administration and rat rectally approach to carry out the prostate suppository acute toxicity test simultaneously, the target organ that observation toxic reaction that animal produced and toxic reaction may occur, for the detection of clinical toxicity provides reference frame, for long term toxicity test provides information and reference frame.(1) the oral acute toxicity test of mice: select KM kind mice, irritate the mode of stomach (ig) administration and carry out oral acute toxicity test, give Herba Saussureae Involueratae prostate suppository extractum liquid with Cmax 750mg/ml, the disposable filling stomach of maximum volume 0.4ml/10g → 148g (crude drug)/kg, observe the toxic reaction and the death condition of mice appearance in 14 days continuously.The result shows, Herba Saussureae Involueratae prostate suppository extractum liquid gastric infusion, and MTD＞148g (crude drug)/kg, the clinical plan of behaving is not seen drug-induced toxic reaction, the i.e. oral avirulence of this medicine this moment with 1187 times of dosage.(2) rectum acute toxicity test: select the SD rat to carry out the rectum acute toxicity test, with 50 times of Herba Saussureae Involueratae prostate suppository extractum liquid clinical dosage (35g crude drug/kg), concentration (709mg/ml), the disposable rectum of the maximum rectally volume (1ml/100g) of rat gives rat, observes the toxic reaction and the death condition of rat appearance in 14 days continuously.The result shows, Herba Saussureae Involueratae prostate suppository extractum liquid rat single rectally, and MTD＞35g crude drug/kg does not see drug-induced toxic reaction and death condition, Herba Saussureae Involueratae prostate suppository extractum liquid single rectally avirulence under this dosage.
(1), the oral acute toxicity test of mice
Summary: after [purpose] investigates Herba Saussureae Involueratae prostate suppository single-dose, the target organ that toxic reaction that animal produced and toxic reaction may occur.Measure the acute toxicity parameter of Herba Saussureae Involueratae prostate suppository, for long term toxicity test provides information and reference frame to mice.[method] selects KM kind mice, irritates the mode of stomach (ig) administration and carries out oral acute toxicity test, with Cmax, the disposable Herba Saussureae Involueratae prostate suppository extractum liquid that gives of maximum volume, observes the toxic reaction and the death condition of mice appearance in 14 days continuously.[result] mice Herba Saussureae Involueratae prostate suppository extractum liquid gastric infusion, MTD＞148g (crude drug)/kg, the clinical plan of behaving is not seen drug-induced toxic reaction this moment with 1187 times of dosage.
Test method: through the qualified mice of quarantining, fasting be can't help water 12 hours before test, selected body weight 20 ± 2g, 40, divided matched group and administration group at random, 20 every group.End fasting in 2 hours after the administration.Observed 14 days continuously, observe the mouse toxicity response situation, the itemized record symptom occurs, increases the weight of, alleviates or the time of death and the size of animal of appearance reaction, calculates the animal dead rate.Put to death surviving animals on the 14th day, dissect, perusal internal organs situation is calculated the multiple of the clinical plan of MTD value and people with dosage.
Experimental result: dead mouse situation and MTD
The dead mouse situation
The oral acute toxicity test animal dead of table 1 Herba Saussureae Involueratae prostate suppository extractum liquid mice situation
MTD result of calculation
Tolerance dose 2.96g (crude drug)/20g of every mice, thus can calculate MTD=148g (crude drug)/kg.
Body weight:
The oral acute toxicity test body weight of table 2 Herba Saussureae Involueratae prostate suppository extractum liquid mice table (X ± SD)
Administration group and matched group compare, P＞0.05.
Table 3, the oral acute toxicity test body weight change of Herba Saussureae Involueratae prostate suppository extractum liquid mice be table (X ± SD) as a result
Administration group and matched group compare, P＞0.05.
Conclusion: Herba Saussureae Involueratae prostate suppository extractum liquid mice oral administration acute toxicity parameter: under this experiment condition, Herba Saussureae Involueratae prostate suppository extractum liquid oral administration records the maximum tolerated dose multiple and behaves clinical plan with 1187 times of dosage, MTD＞148g (crude drug)/kg, oral avirulence.Toxic reaction: toxic reaction mainly shows as transient activity to be reduced, and promptly recovers normal after 2 hours.
(2), rat rectally acute toxicity test
Summary: after [purpose] investigated Herba Saussureae Involueratae prostate suppository rectum single-dose, the target organ that toxic reaction that animal produced and toxic reaction may occur was for the detection of clinical toxicity provides reference frame.Measure the acute toxicity parameter of Herba Saussureae Involueratae prostate suppository, provide reference frame for calculating new drug relative toxicity parameter and long term toxicity, cumulative toxicity and specific toxicity test dose to rat.
[method] selects the SD rat to carry out rectum single-dose toxicity test, and rat is with 50 times, the disposable Herba Saussureae Involueratae prostate suppository extractum liquid that gives of maximum volume of clinical dosage, the toxic reaction and the death condition of observing rat appearance in 14 days continuously.[result] Herba Saussureae Involueratae prostate suppository extractum liquid rat rectally, MTD＞35g crude drug/kg does not see drug-induced toxic reaction, pathological anatomy is not seen the obvious pathological change of Rats Organs and Tissues.
Test method: the SD rat through quarantining qualified, select body weight 220-250g, 20, be divided into matched group and administration group at random, 10 every group.Fasting be can't help water after 12 hours before experiment, and spongy embolus is filled in the rat internal rectum, inserted the perfusion syringe needle from the rectum edge, and slowly pushing syringe makes medicinal liquid soak into spongy embolus, end fasting in 2 hours after the administration.Timing immediately after the administration, the reaction that observe at once, 2h, 4h, 6h animal occurs.Tested the 2nd day to the 14th day, every morning observes once, and observe once afternoon, and the record toxic reaction occurs, increases the weight of, alleviates or the time of death and the size of animal of appearance reaction, calculates the animal dead rate.Before taking by weighing administration, observe mid-term, observe the weight of animals of tailend.Put to death animal on the 14th day, analyse, the perusal mucous membrane of rectum changes each tissue, organ disease situation.If pathological changes person is arranged, use 15% formalin fixed, the routine paraffin wax embedded section, HE dyeing, the light border is checked.
Experimental result:
The rats death situation
Table 1 Herba Saussureae Involueratae prostate suppository extractum liquid rectum acute toxicity test animal dead situation
Body weight
Table 2 Herba Saussureae Involueratae prostate suppository extractum liquid rat rectum acute toxicity test body weight observation table (X ± SD)
Administration group and matched group compare, P＞0.05.
Table 3 Herba Saussureae Involueratae prostate suppository extractum liquid rat rectum acute toxicity test body weight change is table (X ± SD) as a result
Administration group and matched group compare, P＞0.05.
Conclusion:
Herba Saussureae Involueratae prostate suppository extractum liquid rat rectally acute toxicity parameter: under this experiment condition, Herba Saussureae Involueratae prostate suppository extractum liquid rat rectally, MTD＞35g crude drug/kg, Herba Saussureae Involueratae prostate suppository extractum liquid single rectally avirulence.Toxic reaction: toxic reaction mainly shows as movable the minimizing on clinical sign, recovers normal after 2 hours, to not obviously influence of rat body weight.Pathological anatomy does not see that internal organs have tangible drug-induced pathological change.
Long term toxicity test:
Herba Saussureae Involueratae prostate suppository 8.4g, 16.8g, 33.6g (crude drug)/Kg (be equivalent to intend recommend clinical dosage 12,24,48 times) irritate stomach and give rat, and negative control group is irritated stomach and given equal-volume 0.5%CMC-Na.Be administered once every day, and after administration 3 months and 6 months, get 13 rats for every group, hematology, blood biochemical, blood clotting, blood electrolyte index are measured in the ventral aorta blood sampling, carry out after rat is put to death that system becomes celestial and histopathological examination.Each group residue rat is discontinued medication, and continues to feed and observes, and gets blood after 1 month and puts to death, and carries out The reversible experiment.The result shows, from the hematological indices check result as seen, mid-term: each dosage group and negative control group relatively, every index there are no significant difference (P＞0.05).Latter stage: the mean corpuscular hemoglobin concentration (MCHC) of three dosage groups (MCHC) and negative control group relatively all have significant difference (P＜0.05), all the other every indexs there are no significant difference (P＞0.05).Convalescent period: each dosage group and negative control group relatively, every index there are no significant difference (P＞0.05); Learn the index check result as seen from blood biochemical, mid-term: high dose group creatine kinase (CK) relatively has a declining tendency with negative control group, and significant difference (P＜0.05) is arranged; Low dose group triglyceride (TG) and the negative control group trend that relatively significantly decreases has significant difference (P＜0.01).All the other every indexs there are no significant difference (P＞0.05).Latter stage: each dosage group and negative control group relatively, every index there are no significant difference (P＞0.05).Convalescent period: each dosage group and negative control group relatively, every index there are no significant difference (P＞0.05); From blood electrolyte index check result as seen, mid-term: each dosage group and negative control group relatively, every index there are no significant difference (P＞0.05).Latter stage: each dosage group and negative control group relatively, every index there are no significant difference (P＞0.05).Convalescent period: each dosage group and negative control group relatively, every index there are no significant difference (P＞0.05); From blood clotting index check result as seen, mid-term: each dosage group and negative control group relatively, every index there are no significant difference (P＞0.05).Latter stage: each dosage group and negative control group relatively, every index there are no significant difference (P＞0.05).Convalescent period: each dosage group and negative control group relatively, every index there are no significant difference (P＞0.05).The histopathological examination result shows that mid-term, latter stage, convalescent period are respectively organized organs and tissues pathological examination no abnormality seen; Each dosage treated animal main organs does not find that all tangible drug-induced infringement sexually revises.
Experimental technique and result:
Test grouping: rat is weighed, and is divided into 4 groups at random with the body weight equilibrium, i.e. negative control group, low dosage administration group, middle dosed administration group and high dose administration group, 40 every group.
Medication: ig once a day, amounts to 6 months.The clinical administration approach is a rectally, we think that rectally can not guarantee that medicine is in the intrarectal time of staying in the rat repetitively administered toxicity test process, the toxic reaction that shows can not demonstrate fully the toxic reaction of medicine, so we select oral administration.
The mucous membrane of rectum irritation test
Select the SD rat to carry out Herba Saussureae Involueratae prostate suppository rectum multiple dosing irritation test, rat rectally dosage is the clinical application amount, and establish vehicle group and blank group, successive administration and observing 7 days behind the last administration 24h, is analysed 6 animals for every group, take out the rectum local organization, observe mucous membrane of rectum and have or not situations such as hyperemia, redness, judge with the integral estimation method whether medicine has zest to mucous membrane of rectum, and carry out histopathological examination.If check result has unusually, then the animal of drug withdrawal observation need be cooked histopathological examination; If check result is no abnormal, then the animal of drug withdrawal observation need not cooked histopathological examination.The result shows: the Herba Saussureae Involueratae prostate suppository is repeatedly behind the rectally, zootomy is not seen phenomenons such as drug-induced mucous membrane of rectum hyperemia, redness, judge medicine to the mucous membrane of rectum nonirritant with the integral estimation method, histopathological examination does not see that the rat mucous membrane of rectum has drug-induced pathological change.
Test method: through the qualified rat of quarantining, fasting be can't help water 4 hours before experiment, took by weighing every rat body weight, selected body weight 220-250g, 30, was divided into 3 groups at random, 10 every group.End fasting in 2 hours after the administration.Successive administration was observed 7 days, observed the rat toxicity response situation, and the itemized record symptom occurs, increases the weight of, alleviates or the time of death and the size of animal of appearance reaction, calculates the animal dead rate.The 8th day every group analyse 6 animals, the perusal mucous membrane of rectum has or not situations such as hyperemia, redness, judges with the integral estimation method whether medicine has zest to mucous membrane of rectum, and makes histopathological examination.If check result has unusually, then the animal of reversibility observation need be cooked histopathological examination; If check result is no abnormal, then the animal of drug withdrawal observation only need be cooked and analyse observation.Reversibility observing time is 7 days (every group of 4 rats).
Experimental result:
Clinical sign: the Herba Saussureae Involueratae prostate suppository transient activity occurs and reduces after repeatedly rectum gives rat when administration, promptly recovers normal after 2 hours, finishes not see that other toxic reaction is arranged up to the observation period.
The rats death situation
Table 1 Herba Saussureae Involueratae prostate suppository mucous membrane of rectum irritation test rats death situation
Body weight
Table 2 Herba Saussureae Involueratae prostate suppository mucous membrane of rectum irritation test body weight table (X ± SD)
Herba Saussureae Involueratae prostate suppository group and vehicle group and blank group compare, P＞0.05.
Zootomy, integral estimation and histopathological examination
Zootomy is not seen phenomenons such as drug-induced mucous membrane of rectum hyperemia, redness, judges medicine to the mucous membrane of rectum nonirritant with the integral estimation method, and histopathological examination does not see that the rat mucous membrane of rectum has drug-induced pathological change.
Conclusion: under this experiment condition, Herba Saussureae Involueratae prostate suppository rectally is to rat mucous membrane of rectum nonirritant.Zootomy is not seen phenomenons such as drug-induced mucous membrane of rectum hyperemia, redness, judges medicine to the mucous membrane of rectum nonirritant with the integral estimation method, and histopathological examination does not see that the rat mucous membrane of rectum has drug-induced pathological change.
The specific embodiment
The content of each component is among the embodiment 1 (per 1000 (piece)):
A, be ground into fine powder after will Olibanum 150g, Myrrha 150g concocting, and cross 100 mesh sieves, mixing is standby;
B, Rhizoma Curcumae 620g are ground into coarse powder, add 8 times of water gagings, extract volatile oil according to a conventional method 6 hours, and volatile oil device is in addition collected, and is standby;
C, medicinal residues and Herba Saussureae Involueratae 500g, Flos Carthami 350g, rhizoma sparganic 620g add 10 times of amount 80% alcohol reflux 3 times, each 1.5 hours, merging filtrate filters, and it is 1.15～1.20 clear paste that filtrate decompression is concentrated into relative density, vacuum drying gets dry extract, pulverize, mixes mistake 100 mesh sieves with fine powder after Olibanum, Myrrha are pulverized, as mixed powder, standby;
D, Radix Arnebiae (Radix Lithospermi) 1100g add 12 times of amount 95% ethanol and carry out percolation with the speed of per minute 7ml, collect percolate, and be to thick paste, standby at decompression recycling ethanol below 60 ℃;
E, take by weighing S by the amount of 2.3 times of mixed powders
36Mixed fatty glycerides 1.50kg and 1% sodium lauryl sulphate 15g, be heated to molten condition, add mixed powder and thick paste, fully stir evenly, the volatile oil that adds during to 45 ℃ to be cooled, continue to be stirred to evenly, inject the bolt mould, take out the cooling back, make 1000 (piece), every 2.2g, or make paste according to a conventional method and get final product.Said preparation prevents, treats the purposes of the external used medicine of acute and chronic prostatitis, prostatic hyperplasia (hypertrophy) as preparation.
Using method: preceding the rising with morning of sleeping filled in medicine anus 4-6 centimeters after an action of the bowels, and every day 2 times, each one piece or one, one month is a course of treatment.
The content of each component is among the embodiment 2 (per 1000 (piece)):
A, be ground into fine powder after will Olibanum 160g, Myrrha 160g concocting, and cross 100 mesh sieves, mixing is standby;
B, Rhizoma Curcumae 670g are ground into coarse powder, add 8 times of water gagings, extract volatile oil according to a conventional method 6 hours, and volatile oil device is in addition collected, and is standby;
C, medicinal residues and Herba Saussureae Involueratae 580g, Flos Carthami 380g, rhizoma sparganic 680g add 10 times of amount 80% alcohol reflux 3 times, each 1.5 hours, merging filtrate filters, and it is 1.15～1.20 clear paste that filtrate decompression is concentrated into relative density, vacuum drying gets dry extract, pulverize, mixes mistake 100 mesh sieves with fine powder after above-mentioned Olibanum, Myrrha are pulverized, as mixed powder, standby;
D, Radix Arnebiae (Radix Lithospermi) 1140g add 12 times of amount 95% ethanol and carry out percolation with the speed of per minute 7ml, collect percolate, and be to thick paste, standby at decompression recycling ethanol below 60 ℃;
E, take by weighing S by the amount of 2.3 times of mixed powders
36Mixed fatty glycerides 1.80kg and 1% sodium lauryl sulphate 18g; be heated to molten condition; add mixed powder and thick paste, fully stir evenly, the volatile oil that adds during to 45 ℃ to be cooled; continue to be stirred to evenly; inject the bolt mould, take out the cooling back, make 1000 or piece; every 2.2g, or make paste according to a conventional method and get final product.Said preparation prevents, treats the purposes of the external used medicine of acute and chronic prostatitis, prostatic hyperplasia (hypertrophy) as preparation.
Using method: preceding the rising with morning of sleeping filled in medicine anus 4-6 centimeters after an action of the bowels, and every day 2 times, each one piece or one, one month is a course of treatment.
The content of each component is among the embodiment 3 (per 1000 (piece)):
A, be ground into fine powder after will Olibanum 180g, Myrrha 180g concocting, and cross 100 mesh sieves, mixing is standby;
B, Rhizoma Curcumae 640g are ground into coarse powder, add 8 times of water gagings, extract volatile oil according to a conventional method 6 hours, and volatile oil device is in addition collected, and is standby;
C, medicinal residues and Herba Saussureae Involueratae 530g, Flos Carthami 370g, rhizoma sparganic 650g add 10 times of amount 80% alcohol reflux 3 times, each 1.5 hours, merging filtrate filters, and it is 1.15～1.20 clear paste that filtrate decompression is concentrated into relative density, vacuum drying gets dry extract, pulverize, mixes mistake 100 mesh sieves with fine powder after Olibanum, Myrrha are pulverized, as mixed powder, standby;
D, Radix Arnebiae (Radix Lithospermi) 1130g add 12 times of amount 95% ethanol and carry out percolation with the speed of per minute 7ml, collect percolate, and be to thick paste, standby at decompression recycling ethanol below 60 ℃;
E, take by weighing S by the amount of 2.3 times of mixed powders
36Mixed fatty glycerides 1.80kg and 1% sodium lauryl sulphate 18g; be heated to molten condition; add mixed powder and thick paste, fully stir evenly, the volatile oil that adds during to 45 ℃ to be cooled; continue to be stirred to evenly; inject the bolt mould, take out the cooling back, make 1000 or piece; every 2.2g, or make paste according to a conventional method and get final product.Said preparation prevents, treats the purposes of the external used medicine of acute and chronic prostatitis, prostatic hyperplasia (hypertrophy) as preparation.
Using method: preceding the rising with morning of sleeping filled in medicine anus 4-6 centimeters after an action of the bowels, and every day 2 times, each one piece or one, one month is a course of treatment.
The content of each component is among the embodiment 4 (per 1000 (piece)):
A, be ground into fine powder after will Olibanum 200g, Myrrha 200g concocting, and cross 100 mesh sieves, mixing is standby;
B, Rhizoma Curcumae 690g are ground into coarse powder, add 8 times of water gagings, extract volatile oil according to a conventional method 6 hours, and volatile oil device is in addition collected, and is standby;
C, medicinal residues and Herba Saussureae Involueratae 600g, Flos Carthami 400g, rhizoma sparganic 690g add 10 times of amount 80% alcohol reflux 3 times, each 1.5 hours, merging filtrate filters, and it is 1.15～1.20 clear paste that filtrate decompression is concentrated into relative density, vacuum drying gets dry extract, pulverize, mixes mistake 100 mesh sieves with fine powder after Olibanum, Myrrha are pulverized, as mixed powder, standby;
D, Radix Arnebiae (Radix Lithospermi) 1150g add 12 times of amount 95% ethanol and carry out percolation with the speed of per minute 7ml, collect percolate, and be to thick paste, standby at decompression recycling ethanol below 60 ℃;
E, take by weighing S by the amount of 2.3 times of mixed powders
36Mixed fatty glycerides 2.0kg and 1% sodium lauryl sulphate 20g; be heated to molten condition; add mixed powder and thick paste, fully stir evenly, the volatile oil that adds during to 45 ℃ to be cooled; continue to be stirred to evenly; inject the bolt mould, take out the cooling back, make 1000 or piece; every 2.2g, or make paste according to a conventional method and get final product.Said preparation prevents, treats the purposes of the external used medicine of acute and chronic prostatitis, prostatic hyperplasia (hypertrophy) as preparation.
Using method: preceding the rising with morning of sleeping filled in medicine anus 4-6 centimeters after an action of the bowels, and every day 2 times, each one piece or one, one month is a course of treatment.
Claims (3)
1. the medicine for external use snow lotus preparation for treating prostate disease of a control acute and chronic prostatitis, prostatic hyperplasia, prostate hyperplasia genitourinary system; it is characterized in that said preparation is by crude drug Herba Saussureae Involueratae 500-600g, Flos Carthami 350-400g, Radix Arnebiae (Radix Lithospermi) 1100-1150g, Rhizoma Curcumae 620-690g, rhizoma sparganic 620-690g, Olibanum 150200g and Myrrha 150-200g; adjuvant is that mixed fatty glycerides 1.40-1.80kg and 1% sodium lauryl sulphate 15-20g make, with per 1000 or piece be radix.
2. the preparation method of snow lotus preparation for treating prostate disease according to claim 1 is characterized in that following these steps to carrying out:
A, will Olibanum, Myrrha is ground into fine powder after concocting, and crosses 100 mesh sieves, mixing is standby;
B, Rhizoma Curcumae are ground into coarse powder, add 8 times of water gagings, extract volatile oil according to a conventional method 6 hours, and volatile oil device is in addition collected, and is standby;
C, medicinal residues and Herba Saussureae Involueratae, Flos Carthami, rhizoma sparganic add 10 times of amount 80% alcohol reflux 3 times, each 1.5 hours, merging filtrate filters, and it is 1.15～1.20 clear paste that filtrate decompression is concentrated into relative density, vacuum drying gets dry extract, pulverize, mixes mistake 100 mesh sieves with fine powder after above-mentioned Olibanum, Myrrha are pulverized, as mixed powder, standby;
D, Radix Arnebiae (Radix Lithospermi) add 12 times of amount 95% ethanol and carry out percolation with the speed of per minute 7ml, collect percolate, and be to thick paste, standby at decompression recycling ethanol below 60 ℃;
E, take by weighing S by the amount of 2.3 times of mixed powders
36Mixed fatty glycerides contains 1% sodium lauryl sulphate; be heated to molten condition; add mixed powder and thick paste, fully stir evenly, the volatile oil that adds during to 45 ℃ to be cooled; continue to be stirred to evenly; inject the bolt mould, take out the cooling back, make 1000 or piece; every 2.2g, or make paste according to a conventional method and get final product.
The described snow lotus preparation for treating prostate disease of claim 1 in preparation prevention, treat the purposes aspect the external used medicine of acute and chronic prostatitis, prostatic hyperplasia, prostate hyperplasia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100842950A CN100408085C (en) | 2006-05-30 | 2006-05-30 | Snow lotus preparation for treating prostate disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100842950A CN100408085C (en) | 2006-05-30 | 2006-05-30 | Snow lotus preparation for treating prostate disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1883694A CN1883694A (en) | 2006-12-27 |
| CN100408085C true CN100408085C (en) | 2008-08-06 |
Family
ID=37582078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100842950A Active CN100408085C (en) | 2006-05-30 | 2006-05-30 | Snow lotus preparation for treating prostate disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100408085C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107029179A (en) * | 2017-04-19 | 2017-08-11 | 上海裕家农业科技发展有限公司 | A kind of paste for treating prostate and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1383860A (en) * | 2002-05-21 | 2002-12-11 | 崔行善 | Medicine for treating bladder cancer |
-
2006
- 2006-05-30 CN CNB2006100842950A patent/CN100408085C/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1383860A (en) * | 2002-05-21 | 2002-12-11 | 崔行善 | Medicine for treating bladder cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1883694A (en) | 2006-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102145126B (en) | Pharmaceutical composition for treating xerophthalmia | |
| CN102058715B (en) | Chinese medicine preparation for treating chronic prostatitis and preparation method thereof | |
| CN102225181B (en) | Medicament for treating benign prostatic hyperplasia disease and preparation method thereof | |
| US11129863B2 (en) | Composition, preparation method thereof, and application thereof in the prevention and treatment of mammary gland disease | |
| CN102716184A (en) | Chinese medicinal composition and application thereof | |
| CN100417402C (en) | Liposoluble traditional medicine bougie for treating acute and chronic prostatitis, and manufacturing technique thereof | |
| CN1327875C (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
| CN101721528B (en) | Medicine composition for treating chronic prostatitis | |
| CN104208242B (en) | One treats prostatitic external use plaster and preparation method thereof | |
| CN100408085C (en) | Snow lotus preparation for treating prostate disease | |
| CN100389796C (en) | Chinese medicinal preparation for treating chronic prostatitis and its manufacturing method | |
| CN101455715B (en) | Suppository for treating gynecologic diseases and preparation method thereof | |
| CN101361885B (en) | Chinese traditional medicine composition for treating the prostatitis and preparation method thereof | |
| KR100629199B1 (en) | Composition for improving male reproductive function by increasing the concentration of testosterone in blood | |
| CN101559196B (en) | Medicament for treating the hyperplasia of mammary glands and preparation method thereof | |
| CN101816762A (en) | Medicinal preparation for treating colpitis and preparation method thereof | |
| CN1327874C (en) | Chinese medicine formulation for treating chronic prostatitis and its preparing method | |
| CN1943701B (en) | A kind of medicine for treatment of non-gonococcal urethritis(NGU) and its preparation method | |
| CN103720949A (en) | Capsule for relieving constipation and clearing bowels and preparation method thereof | |
| CN108404094A (en) | A kind of thin network analgesic antiphlogistic bee venom application conditioning cream | |
| CN103656063A (en) | Medicine for treating chronic prostatitis | |
| CN108310297A (en) | A kind of drug and preparation method thereof of prevention diabetic keratopathy dysfunction | |
| CN103919961A (en) | Middle and old age kidney-jing deficiency and kidney yang deficiency treatment traditional Chinese medicine preparation and preparation method thereof | |
| CN101264302A (en) | Application of Chinese medicinal composition in preparing medicaments for treating menoxenia and menorrhalgia | |
| CN105031135A (en) | Traditional Chinese medicine composition for treating dysmenorrhea with liver and kidney deficiency syndrome and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: QIKANGHABO UYGUR MEDICINE CO., LTD., XINJIANG Free format text: FORMER OWNER: UYGUR MEDICINE RESEARCH INSTITUTE, XINJIANG UYGUR AUTONOMOUS REGION Effective date: 20110725 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee |
Owner name: UYGUR MEDICINE RESEARCH INSTITUTE, XINJIANG UYGUR Free format text: FORMER NAME: UIGUR MEDICAL INST., UIGUR AUTONOMOUS REGION, XINJIANG;UIGUR MEDICAL INST., UIGUR AUTONOMOUS REGION, XINJIANG |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 830001 AFFILIATED NO. 1, NO. 776, YAN'AN ROAD, URUMQI CITY, XINJIANG UYGHUR AUTONOMOUS REGION TO: 830026 NO. 625, YINGBIN ROAD, URUMQI CITY, XINJIANG UYGHUR AUTONOMOUS REGION |
|
| CP03 | Change of name, title or address |
Address after: 830001 No. 776, Yanan Road, the Xinjiang Uygur Autonomous Region, Urumqi, attached 1 Patentee after: XINJIANG UYGUR AUTONOMOUS REGION UIGHUR MEDICAL Research Institute Address before: 830001 No. 36, Yanan Road, Urumqi, the Xinjiang Uygur Autonomous Region Patentee before: UIHGUR MEDICINE Research Institute XINJI |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110725 Address after: 830026 No. 625 Yingbin Road, the Xinjiang Uygur Autonomous Region, Urumqi Patentee after: QIKANGHABO UGGR MEDICINE Co.,Ltd. Address before: 830001 No. 776, Yanan Road, the Xinjiang Uygur Autonomous Region, Urumqi, attached 1 Patentee before: Xinjiang Uygur Autonomous Region Uighur Medical Research Institute |
|
| C56 | Change in the name or address of the patentee |
Owner name: XINJIANG QIKANG HABO UIGUR MEDICINE CO., LTD. Free format text: FORMER NAME: QIKANGHABO UYGUR MEDICINE CO., LTD., XINJIANG |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 830026 No. 625 Yingbin Road, the Xinjiang Uygur Autonomous Region, Urumqi Patentee after: XINJIANG QIKANG HABO UIGHUR MEDICINE CO.,LTD. Address before: 830026 No. 625 Yingbin Road, the Xinjiang Uygur Autonomous Region, Urumqi Patentee before: QIKANGHABO UGGR MEDICINE Co.,Ltd. |
|
| CP03 | Change of name, title or address |
Address after: 830000 the Xinjiang Uygur Autonomous Region Urumqi hi tech Industrial Development Zone (new urban area) 1375 Patentee after: New Qikang Pharmaceutical Co.,Ltd. Address before: 830026 Yingbin Road, Urumqi, the Xinjiang Uygur Autonomous Region 625 Patentee before: XINJIANG QIKANG HABO UIGHUR MEDICINE CO.,LTD. |
|
| CP03 | Change of name, title or address |